1. Home
  2. ZVRA
  3. ZVRA News

Latest Zevra Therapeutics Inc. (ZVRA) News on March 28, 2025

Zevra Therapeutics Independent Director Acquires 33% More Stock
ZVRA

Simply Wall St.

5 days ago

Zevra Therapeutics Independent Director Acquires 33% More Stock

Zevra Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags
ZVRA

Simply Wall St.

15 days ago

Zevra Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

ZVRA

MT Newswires

16 days ago

Sector Update: Health Care Stocks Decline Wednesday Afternoon

ZVRA

Thomson Reuters StreetEvents

16 days ago

Q4 2024 Zevra Therapeutics Inc Earnings Call

Zevra Therapeutics Inc (ZVRA) Q4 2024 Earnings Call Highlights: Record Revenue and Strategic ...
ZVRA

GuruFocus.com

17 days ago

Zevra Therapeutics Inc (ZVRA) Q4 2024 Earnings Call Highlights: Record Revenue and Strategic ...

Zevra Therapeutics (ZVRA) Reports Q4 Loss, Tops Revenue Estimates
ZVRA

Zacks

17 days ago

Zevra Therapeutics (ZVRA) Reports Q4 Loss, Tops Revenue Estimates

ZVRA

Associated Press Finance

17 days ago

Zevra Therapeutics: Q4 Earnings Snapshot

ZVRA

MT Newswires

17 days ago

Zevra Therapeutics Q4 Net Loss Widens, Revenue Decreases; Shares Fall After Hours

Zevra Reports Full Year 2024 and Fourth Quarter Financial Results
ZVRA

GlobeNewswire

17 days ago

Zevra Reports Full Year 2024 and Fourth Quarter Financial Results

Investing in Zevra Therapeutics (NASDAQ:ZVRA) five years ago would have delivered you a 83% gain
ZVRA

Simply Wall St.

24 days ago

Investing in Zevra Therapeutics (NASDAQ:ZVRA) five years ago would have delivered you a 83% gain

Zevra Launches New Disease State Awareness Campaign, ‘Learn NPC, Read Between the Signs,’ to Drive Early Recognition and Treatment of Niemann-Pick Disease Type C
ZVRA

GlobeNewswire

a month ago

Zevra Launches New Disease State Awareness Campaign, ‘Learn NPC, Read Between the Signs,’ to Drive Early Recognition and Treatment of Niemann-Pick Disease Type C

Praxis hits trial setback; Bristol Myers lays off staff in New Jersey
ZVRA

BioPharma Dive

a month ago

Praxis hits trial setback; Bristol Myers lays off staff in New Jersey

Zevra sells priority review voucher for $150m to support drug launches
ZVRA

Pharmaceutical Technology

a month ago

Zevra sells priority review voucher for $150m to support drug launches

ZVRA

MT Newswires

a month ago

Zevra Therapeutics to Sell Priority Review Voucher for $150 Million

Zevra Therapeutics Enters Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million
ZVRA

GlobeNewswire

a month ago

Zevra Therapeutics Enters Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million

Zevra to Report 2024 Fourth Quarter and Full Year Financial Results
ZVRA

GlobeNewswire

a month ago

Zevra to Report 2024 Fourth Quarter and Full Year Financial Results

Zevra to Participate at Upcoming Investor Conferences
ZVRA

GlobeNewswire

a month ago

Zevra to Participate at Upcoming Investor Conferences

ZVRA

MT Newswires

a month ago

Zevra Therapeutics Insider Sold Shares Worth $727,390, According to a Recent SEC Filing

Zevra Therapeutics to Present at the 21st Annual WORLDSymposium™
ZVRA

GlobeNewswire

2 months ago

Zevra Therapeutics to Present at the 21st Annual WORLDSymposium™

Zevra Therapeutics to Participate at Upcoming Investor Conferences
ZVRA

GlobeNewswire

2 months ago

Zevra Therapeutics to Participate at Upcoming Investor Conferences

Positive Signs As Multiple Insiders Buy Zevra Therapeutics Stock
ZVRA

Simply Wall St.

2 months ago

Positive Signs As Multiple Insiders Buy Zevra Therapeutics Stock

Analysts Expect Breakeven For Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Before Long
ZVRA

Simply Wall St.

3 months ago

Analysts Expect Breakeven For Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Before Long

ZVRA

MT Newswires

3 months ago

Zevra Therapeutics to Join Nasdaq Biotechnology Index

Zevra Therapeutics to be Added to Nasdaq Biotechnology Index (Nasdaq: NBI) Effective December 23, 2024
ZVRA

GlobeNewswire

3 months ago

Zevra Therapeutics to be Added to Nasdaq Biotechnology Index (Nasdaq: NBI) Effective December 23, 2024

A drug for fewer than 1,000 patients? Awareness and diagnosis are key.
ZVRA

Pharma Voice

4 months ago

A drug for fewer than 1,000 patients? Awareness and diagnosis are key.

Zevra Therapeutics Announces Organizational Changes
ZVRA

GlobeNewswire

4 months ago

Zevra Therapeutics Announces Organizational Changes

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) has caught the attention of institutional investors who hold a sizeable 42% stake
ZVRA

Simply Wall St.

4 months ago

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) has caught the attention of institutional investors who hold a sizeable 42% stake

Zevra Therapeutics to Participate at Upcoming Investor Conferences
ZVRA

GlobeNewswire

4 months ago

Zevra Therapeutics to Participate at Upcoming Investor Conferences

Zevra Therapeutics Launches MIPLYFFA for Niemann-Pick Disease
ZVRA

TipRanks

4 months ago

Zevra Therapeutics Launches MIPLYFFA for Niemann-Pick Disease

Zevra Therapeutics Announces U.S. Commercial Availability of MIPLYFFA™ (arimoclomol) for Treatment of Niemann-Pick Disease Type C
ZVRA

GlobeNewswire

4 months ago

Zevra Therapeutics Announces U.S. Commercial Availability of MIPLYFFA™ (arimoclomol) for Treatment of Niemann-Pick Disease Type C

Analysts Have Made A Financial Statement On Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Third-Quarter Report
ZVRA

Simply Wall St.

4 months ago

Analysts Have Made A Financial Statement On Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Third-Quarter Report

Zevra Therapeutics Third Quarter 2024 Earnings: Misses Expectations
ZVRA

Simply Wall St.

4 months ago

Zevra Therapeutics Third Quarter 2024 Earnings: Misses Expectations

Zevra Therapeutics Inc (ZVRA) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst ...
ZVRA

GuruFocus.com

5 months ago

Zevra Therapeutics Inc (ZVRA) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst ...

Zevra Therapeutics (ZVRA) Reports Q3 Loss, Lags Revenue Estimates
ZVRA

Zacks

5 months ago

Zevra Therapeutics (ZVRA) Reports Q3 Loss, Lags Revenue Estimates

ZVRA

Associated Press Finance

5 months ago

Zevra Therapeutics: Q3 Earnings Snapshot

Zevra Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Updates
ZVRA

GlobeNewswire

5 months ago

Zevra Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Updates

Assertio (ASRT) Reports Q3 Loss, Lags Revenue Estimates
ZVRA

Zacks

5 months ago

Assertio (ASRT) Reports Q3 Loss, Lags Revenue Estimates

Zevra Therapeutics to Present Data Demonstrating Relevance of Swallow Domain in Niemann-Pick Disease Type C Clinical Severity Scale at 53rd Child Neurology Society Annual Meeting
ZVRA

GlobeNewswire

5 months ago

Zevra Therapeutics to Present Data Demonstrating Relevance of Swallow Domain in Niemann-Pick Disease Type C Clinical Severity Scale at 53rd Child Neurology Society Annual Meeting

Zevra Therapeutics Inc (ZVRA) Q3 2024: Everything You Need To Know Ahead Of Earnings
ZVRA

GuruFocus.com

5 months ago

Zevra Therapeutics Inc (ZVRA) Q3 2024: Everything You Need To Know Ahead Of Earnings

Zevra Therapeutics to Participate at the Guggenheim Securities Healthcare Innovation Conference on Wed, Nov. 13
ZVRA

GlobeNewswire

5 months ago

Zevra Therapeutics to Participate at the Guggenheim Securities Healthcare Innovation Conference on Wed, Nov. 13

Zevra Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Nov. 12, 2024
ZVRA

GlobeNewswire

5 months ago

Zevra Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Nov. 12, 2024

Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
ZVRA

Zacks

5 months ago

Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Earnings Preview: Zevra Therapeutics (ZVRA) Q3 Earnings Expected to Decline
ZVRA

Zacks

5 months ago

Earnings Preview: Zevra Therapeutics (ZVRA) Q3 Earnings Expected to Decline

Zevra Therapeutics to Participate in Rare Disease Panel at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC
ZVRA

GlobeNewswire

6 months ago

Zevra Therapeutics to Participate in Rare Disease Panel at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC

Zevra Therapeutics Inc (ZVRA) Q2 2024 Earnings Call Highlights: Strategic Advancements Amid ...
ZVRA

GuruFocus.com

6 months ago

Zevra Therapeutics Inc (ZVRA) Q2 2024 Earnings Call Highlights: Strategic Advancements Amid ...

NUCDF and Zevra Therapeutics Launch Check Ammonia Campaign to Highlight Critical Importance of Prompt, Accurate Blood Ammonia Testing for Diagnosing Urea Cycle Disorders
ZVRA

GlobeNewswire

6 months ago

NUCDF and Zevra Therapeutics Launch Check Ammonia Campaign to Highlight Critical Importance of Prompt, Accurate Blood Ammonia Testing for Diagnosing Urea Cycle Disorders

ZVRA

MT Newswires

6 months ago

Guggenheim Initiates Zevra Therapeutics With Buy Rating, $20 Price Target

Zevra Stock Surges Close to 70% in 3 Months: Here's Why
ZVRA

Zacks

6 months ago

Zevra Stock Surges Close to 70% in 3 Months: Here's Why

Biotech Stock Roundup: BHVN, WVE, ZVRA Stocks Up on Updates, BIIB & UCBs Study Data & More
ZVRA

Zacks

6 months ago

Biotech Stock Roundup: BHVN, WVE, ZVRA Stocks Up on Updates, BIIB & UCBs Study Data & More

Investors in Zevra Therapeutics (NASDAQ:ZVRA) have seen decent returns of 67% over the past year
ZVRA

Simply Wall St.

6 months ago

Investors in Zevra Therapeutics (NASDAQ:ZVRA) have seen decent returns of 67% over the past year

Zevra Therapeutics (ZVRA) Moves 9.1% Higher: Will This Strength Last?
ZVRA

Zacks

6 months ago

Zevra Therapeutics (ZVRA) Moves 9.1% Higher: Will This Strength Last?

Zevra Therapeutics to Present Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at Sleep Europe 2024
ZVRA

GlobeNewswire

6 months ago

Zevra Therapeutics to Present Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at Sleep Europe 2024

ZVRA

MT Newswires

6 months ago

JMP Securities Initiates Zevra Therapeutics at Outperform

FDA approves Zevra Therapeutics’ Miplyffa for Niemann-Pick disease
ZVRA

Pharmaceutical Technology

6 months ago

FDA approves Zevra Therapeutics’ Miplyffa for Niemann-Pick disease

Zevra Therapeutics' Drug Becomes First FDA-Approved Treatment For Ultra-Rare Neurodegenerative Disease
ZVRA

Benzinga

6 months ago

Zevra Therapeutics' Drug Becomes First FDA-Approved Treatment For Ultra-Rare Neurodegenerative Disease

Zevra Therapeutics’ MIPLYFFA™ (arimoclomol) Receives U.S. FDA Approval as Treatment for Niemann-Pick Disease Type C
ZVRA

GlobeNewswire

6 months ago

Zevra Therapeutics’ MIPLYFFA™ (arimoclomol) Receives U.S. FDA Approval as Treatment for Niemann-Pick Disease Type C

ZVRA

MT Newswires

6 months ago

Zevra Therapeutics Gets US FDA Approval For Miplyffa

Zevra Therapeutics Presented New Data for Arimoclomol and OLPRUVA® (Sodium Phenylbutyrate) at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium
ZVRA

GlobeNewswire

7 months ago

Zevra Therapeutics Presented New Data for Arimoclomol and OLPRUVA® (Sodium Phenylbutyrate) at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium

Zevra Therapeutics to Participate at Upcoming Investor Conferences
ZVRA

GlobeNewswire

7 months ago

Zevra Therapeutics to Participate at Upcoming Investor Conferences

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Just Reported And Analysts Have Been Cutting Their Estimates
ZVRA

Simply Wall St.

7 months ago

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Just Reported And Analysts Have Been Cutting Their Estimates

ZVRA

MT Newswires

7 months ago

Zevra Therapeutics Q2 Net Loss Widens, Revenue Slumps

Zevra Therapeutics (ZVRA) Reports Q2 Loss, Tops Revenue Estimates
ZVRA

Zacks

7 months ago

Zevra Therapeutics (ZVRA) Reports Q2 Loss, Tops Revenue Estimates

ZVRA

Associated Press Finance

7 months ago

Zevra Therapeutics: Q2 Earnings Snapshot

Zevra Therapeutics Reports Second Quarter 2024 Financial Results and Corporate Highlights
ZVRA

GlobeNewswire

7 months ago

Zevra Therapeutics Reports Second Quarter 2024 Financial Results and Corporate Highlights

ZVRA

MT Newswires

8 months ago

Zevra Therapeutics Prices $60 Million Stock Offering

Zevra Therapeutics Announces Pricing of Underwritten Offering of Common Stock
ZVRA

GlobeNewswire

8 months ago

Zevra Therapeutics Announces Pricing of Underwritten Offering of Common Stock

Zevra Therapeutics Announces Proposed Public Offering of Common Stock
ZVRA

GlobeNewswire

8 months ago

Zevra Therapeutics Announces Proposed Public Offering of Common Stock

Zevra Therapeutics to Present at Canaccord Genuity’s 44th Annual Growth Conference
ZVRA

GlobeNewswire

8 months ago

Zevra Therapeutics to Present at Canaccord Genuity’s 44th Annual Growth Conference

Earnings Preview: Zevra Therapeutics (ZVRA) Q2 Earnings Expected to Decline
ZVRA

Zacks

8 months ago

Earnings Preview: Zevra Therapeutics (ZVRA) Q2 Earnings Expected to Decline

ZVRA

MT Newswires

8 months ago

Top Midday Gainers

Zevra wins FDA panel backing for previously rejected arimoclomol
ZVRA

Pharmaceutical Technology

8 months ago

Zevra wins FDA panel backing for previously rejected arimoclomol

FDA Advisory Committee Votes Favorably that the Data Support Arimoclomol as Effective Treatment for Patients with Niemann-Pick Disease Type C
ZVRA

GlobeNewswire

8 months ago

FDA Advisory Committee Votes Favorably that the Data Support Arimoclomol as Effective Treatment for Patients with Niemann-Pick Disease Type C

Zevra Therapeutics to Report Second Quarter 2024 Financial Results
ZVRA

GlobeNewswire

8 months ago

Zevra Therapeutics to Report Second Quarter 2024 Financial Results

Zevra Therapeutics Insider Confidence Rewarded, Stock Hits US$235m Market Cap
ZVRA

Simply Wall St.

9 months ago

Zevra Therapeutics Insider Confidence Rewarded, Stock Hits US$235m Market Cap

Zevra (ZVRA) Rises on Update on Niemann-Pick Disease Type C Drug
ZVRA

Zacks

9 months ago

Zevra (ZVRA) Rises on Update on Niemann-Pick Disease Type C Drug

Zevra Therapeutics (ZVRA) Surges 21.9%: Is This an Indication of Further Gains?
ZVRA

Zacks

9 months ago

Zevra Therapeutics (ZVRA) Surges 21.9%: Is This an Indication of Further Gains?

AbbVie names new R&D head; Arcutis eczema cream approved
ZVRA

BioPharma Dive

9 months ago

AbbVie names new R&D head; Arcutis eczema cream approved

FDA Convenes Expert Panel Meeting For Zevra Therapeutics' Arimoclomol, Analyst Optimistic About Approval Despite Small Patient Base
ZVRA

Benzinga

9 months ago

FDA Convenes Expert Panel Meeting For Zevra Therapeutics' Arimoclomol, Analyst Optimistic About Approval Despite Small Patient Base

Zevra Announces FDA Advisory Committee Meeting to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C
ZVRA

GlobeNewswire

9 months ago

Zevra Announces FDA Advisory Committee Meeting to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C

Zevra Therapeutics Expands Executive Leadership Team
ZVRA

GlobeNewswire

9 months ago

Zevra Therapeutics Expands Executive Leadership Team

Breakeven On The Horizon For Zevra Therapeutics, Inc. (NASDAQ:ZVRA)
ZVRA

Simply Wall St.

9 months ago

Breakeven On The Horizon For Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

Zevra Therapeutics Transitions to Orsini as the Specialty Pharmacy Provider for OLPRUVA® (sodium phenylbutyrate), a Treatment for Certain Urea Cycle Disorders
ZVRA

GlobeNewswire

9 months ago

Zevra Therapeutics Transitions to Orsini as the Specialty Pharmacy Provider for OLPRUVA® (sodium phenylbutyrate), a Treatment for Certain Urea Cycle Disorders

ZVRA

MT Newswires

10 months ago

Zevra Therapeutics Files $350 Million Mixed-Shelf; Shares Fall After Hours

Zevra Therapeutics Announces Positive Final Results from Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at SLEEP 2024 Annual Meeting
ZVRA

GlobeNewswire

10 months ago

Zevra Therapeutics Announces Positive Final Results from Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at SLEEP 2024 Annual Meeting

Retail investors account for 59% of Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) ownership, while institutions account for 28%
ZVRA

Simply Wall St.

10 months ago

Retail investors account for 59% of Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) ownership, while institutions account for 28%

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q1 2024 Earnings Call Transcript
ZVRA

Insider Monkey

a year ago

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q1 2024 Earnings Call Transcript

Zevra Therapeutics to Participate at Upcoming Investor Events
ZVRA

GlobeNewswire

a year ago

Zevra Therapeutics to Participate at Upcoming Investor Events

Zevra Therapeutics First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
ZVRA

Simply Wall St.

a year ago

Zevra Therapeutics First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

ZVRA

GuruFocus.com

a year ago

Zevra Therapeutics Inc (ZVRA) (Q1 2024) Earnings Call Transcript Highlights: Navigating ...

Zevra Therapeutics Inc (ZVRA) Q1 2024 Earnings: Misses EPS Estimates, Revenue Consistent with ...
ZVRA

GuruFocus.com

a year ago

Zevra Therapeutics Inc (ZVRA) Q1 2024 Earnings: Misses EPS Estimates, Revenue Consistent with ...

Zevra Therapeutics (ZVRA) Reports Q1 Loss, Lags Revenue Estimates
ZVRA

Zacks

a year ago

Zevra Therapeutics (ZVRA) Reports Q1 Loss, Lags Revenue Estimates

ZVRA

Associated Press Finance

a year ago

Zevra Therapeutics: Q1 Earnings Snapshot

Zevra Therapeutics Reports First Quarter 2024 Financial Results and Corporate Updates
ZVRA

GlobeNewswire

a year ago

Zevra Therapeutics Reports First Quarter 2024 Financial Results and Corporate Updates

Will OptiNose (OPTN) Report Negative Q1 Earnings? What You Should Know
ZVRA

Zacks

a year ago

Will OptiNose (OPTN) Report Negative Q1 Earnings? What You Should Know

Zevra Therapeutics to Report First Quarter 2024 Results on May 8, 2024
ZVRA

GlobeNewswire

a year ago

Zevra Therapeutics to Report First Quarter 2024 Results on May 8, 2024

Zevra Therapeutics’ President and Chief Executive Officer Issues Letter to Stockholders Highlighting Recent Key Accomplishments and Outlook for 2024
ZVRA

GlobeNewswire

a year ago

Zevra Therapeutics’ President and Chief Executive Officer Issues Letter to Stockholders Highlighting Recent Key Accomplishments and Outlook for 2024

Zevra Therapeutics Presents New Data on the Long-Term Safety and Efficacy of Arimoclomol as a Treatment for Niemann-Pick Disease Type C at the SIMD 45th Annual Meeting
ZVRA

GlobeNewswire

a year ago

Zevra Therapeutics Presents New Data on the Long-Term Safety and Efficacy of Arimoclomol as a Treatment for Niemann-Pick Disease Type C at the SIMD 45th Annual Meeting

Zevra Therapeutics Refinances Existing Debt with up to $100M in Committed Capital under New Credit Facility
ZVRA

GlobeNewswire

a year ago

Zevra Therapeutics Refinances Existing Debt with up to $100M in Committed Capital under New Credit Facility

Zevra Therapeutics Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags
ZVRA

Simply Wall St.

a year ago

Zevra Therapeutics Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags

Bearish: Analysts Just Cut Their Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Revenue and EPS estimates
ZVRA

Simply Wall St.

a year ago

Bearish: Analysts Just Cut Their Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Revenue and EPS estimates

Share on Social Networks: